Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
暂无分享,去创建一个
A. Arakawa | M. Tanabe | Y. Horimoto | M. Saito | Toshiyuki Kobayashi | E. Tokuda | Yuko Ichikawa | Misato Okazaki